Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-effect Bioavailability Study of Gemigliptin/Dapagliflozin/Metformin in Healthy Volunteers
NCT07396844Phase 1Completed
- Sponsor
- LG Chem
- Start
- Jun 2026
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gemigliptin, dapagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by LG Chem. Primary endpoint: Plasma concentration of Gemigliptin, Dapagliflozin and Metformin up to 72 hours. Started Jun 2026; status: completed.
02
Drugs
gemigliptindapagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07396844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07396844.